Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners -- Ignore unavailable to you. Want to Upgrade?

To: Mark Fowler who wrote (3298)	11/21/2000 1:17:11 PM
From: mike machi	Read Replies (1) \| Respond to of 57684

~I don't know if Jnpr will hold its D-top measurement? This is very iffy here.~ I like JNPR.. Under 100. MM

To: Mark Fowler who wrote (3298)	11/21/2000 1:40:30 PM
From: Bill Harmond	Respond to of 57684

From Briefing: Celera Genomics (CRA) 47 +7/8: Banc of America Sec initiates coverage with a STRONG BUY rating and price target of $90; believes CRA is in process of revolutionizing the entire practice of medicine by identifying genetic differences between people called single nucleotide polymorphisms (SNPs) that result in some people getting sick and others being perfectly healthy; catalysts include 2-4 pharmaceutical database subscribers in next six months, submission of the human genome manuscript to a major scientific journal for publication, and proteomics factory set up in six months.